Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MDCX

Medicus Pharma Ltd

Jun 18 • 01:13PM ET

2.54

Dollar change -0.03
Percentage change -1.17	%

Healthcare • Drug Manufacturers - General • Canada • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.43	Insider Own	80.22%	Shs Outstand	13.42M	Perf Week	-4.87%
Market Cap	40.22M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	-0.59%	Shs Float	2.34M	Perf Month	-67.35%
Income	-14.47M	PEG	-	EPS next Q	-0.25	Inst Own	25.73%	Short Float	16.16%	Perf Quarter	-18.33%
Sales	0.00M	P/S	-	EPS this Y	11.21%	Inst Trans	-	Short Ratio	1.84	Perf Half Y	-7.64%
Book/sh	0.16	P/B	15.87	EPS next Y	6.47%	ROA	-435.53%	Short Interest	0.38M	Perf Year	-
Cash/sh	0.25	P/C	10.10	EPS next 5Y	5.68%	ROE	-1882.04%	52W Range	1.80 - 8.94	Perf YTD	4.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROIC	-623.03%	52W High	-71.59%	Beta	-
Dividend TTM	-	Quick Ratio	1.53	Sales past 5Y	-	Gross Margin	-	52W Low	41.11%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	1.53	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	35.14	Volatility	5.24% 12.78%
Employees	12	Debt/Eq	0.13	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	19.67
Option/Short	No / Yes	LT Debt/Eq	0.08	EPS Q/Q	-87.92%	Payout	-	Rel Volume	0.57	Prev Close	2.57
Sales Surprise	-	EPS Surprise	-70.25%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	205.67K	Price	2.54
SMA20	-30.96%	SMA50	-39.52%	SMA200	-26.92%	Trades		Volume	69,991	Change	-1.17%

Jun-12-25 07:30AM	Medicus Pharma Ltd. to Present at 2025 Bio International Convention (Newsfile)
Jun-09-25 07:30AM	Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses (Newsfile)
Jun-02-25 01:40PM	Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering (Newsfile)
May-30-25 07:00AM	Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari (GlobeNewswire) -29.85%
May-29-25 08:30PM	Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering (Newsfile) -11.77%
07:30AM	Loading…
May-22-25 07:30AM	Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (Newsfile) -8.17%
Apr-28-25 07:30AM	Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction (Newsfile)
Apr-21-25 07:30AM	Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) (Newsfile)
Mar-10-25 04:05PM	Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering (Newsfile) +11.48% -23.24%
Mar-06-25 08:30PM	Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering (Newsfile)
07:30AM	Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (Newsfile)
Feb-27-25 07:30AM	Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (GlobeNewswire) +12.16%
Feb-14-25 07:30AM	Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) (GlobeNewswire) +19.48%
Feb-11-25 07:41AM	Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV) (Newsfile)
Dec-12-24 07:30AM	Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch (GlobeNewswire)
07:30AM	Loading…
Dec-02-24 07:30AM	Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region (GlobeNewswire) -8.72%
Nov-18-24 07:30AM	Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer (Newsfile) -6.70%
Nov-15-24 04:47PM	Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States (Newsfile) -15.47%

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VELOCITY FUND PARTNERS, LP	10% Owner	May 20 '25	Sale	7.72	75,000	578,940	3,248,741	May 21 12:57 PM
VELOCITY FUND PARTNERS, LP	Major Shareholders	May 20 '25	Proposed Sale	195.49	118,000	23,067,500		May 20 03:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDCX

Medicus Pharma Ltd

Upgrade your FINVIZ experience